Holen Sie sich die Stockscreener-App
14.83
3.06%
0.44
Handel nachbörslich:
14.83
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co. - MarketBeat
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN - MarketBeat
Design Therapeutics (DSGN) Rises 1.47% as Gene Therapy Plays Draw AttentionAnalyst Upgrade Stocks - dars.gov.et
Design Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22 - moomoo.com
Design Therapeutics Q2 Net Loss Narrows - Moomoo
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Design Therapeutics posts Q2 loss, updates clinical trials - Investing.com
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Design Therapeutics Q2 net loss narrower than expected - TradingView
Design Therapeutics reports $20.2M Q2 net loss, $207.4M cash as RESTORE-FA advances - TradingView
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary - TradingView
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial - Moomoo
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
Design Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Design Therapeutics (NASDAQ: DSGN) highlights FA data alongside Q2 loss - Stock Titan
Design Therapeutics Inc (DSGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Design Therapeutics (DSGN) Edges Higher as Stock Tests Key Resistance LevelALMA Signal - dars.gov.et
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DSGN|Design Therapeutics Inc|Price:13.990|Chg%:+0.220 - TradingKey
DSGN|Design Therapeutics Inc|Price:13.060|Chg%:+0.300 - TradingKey
Design Therapeutics Inc (DSGN) Institutional Confidence - TradingKey
Design Therapeutics Inc (DSGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Balance Sheet - TradingKey
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Design Therapeutics, Inc. Revenue Breakdown – NASDAQ:DSGN - TradingView
DSGN|Design Therapeutics Inc|Price:11.780|Chg%:+0.150 - TradingKey
Edgewise Therapeutics, Inc. (EWTX) options chain - Yahoo Finance Singapore
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate - Moomoo
Fuchs Dystrophy Pipeline 2026: Therapies Under Investigation, - openPR.com
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history - Yahoo Finance UK
Cellares and Papillon partner for PPL-001 manufacturing automation - Yahoo Finance
Design Therapeutics (DSGN) Q1 2026 earnings summary - Quartr
Design Therapeutics (DSGN) Leerink Global Healthcare Conference 2026 Summary - Quartr
Design Therapeutics (DSGN) Jefferies London Healthcare Conference 2024 Summary - Quartr
Design Therapeutics (DSGN) Proxy filing Summary - Quartr
Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN
Design Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Shares as Investors Focus on Pipeline ProgressFinancial Health Score - dars.gov.et
DSGN Q1 2026 Earnings: EPS Surprises to the Upside Amid Ongoing Pipeline DevelopmentEPS Surprise History - dars.gov.et
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien - Barchart.com
Myotonic Dystrophy Market Expected to Experience Accelerated - openPR.com
Design Therapeutics (DSGN) Jefferies Global Healthcare Conference 2025 Summary - Quartr
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire
If You Invested $1,000 in Design Therapeutics, Inc. (DSGN) - Stock Titan
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
Cantor Fitzgerald reiterates Design Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Design Therapeutics stock rating By Investing.com - Investing.com Nigeria
Design Therapeutics stock rises on Phase 1 trial dosing start - Investing.com
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com - Investing.com Nigeria
Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com - Investing.com South Africa
Design Therapeutics begins dosing DM1 drug in phase 1 trial - Investing.com
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - The Manila Times
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Smaller-than-Expected Loss Lifts Shares 5.28%Segment Revenue Breakdown - dars.gov.et
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):